Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21265743 | 0.88 | EHMT2 (0.51) | EHMT2CYP2C9USP2LMNAABCC4 | |
| SCHEMBL25887858 | 0.87 | EHMT2 (0.47) | EHMT2CYP2C9USP2LMNAABCC4 | |
| SCHEMBL21265754 | 0.86 | EHMT2 (0.43) | EHMT2CYP2C9USP2LMNAABCC4 | |
| Hydrochloric Acid SCHEMBL23610932 | 0.85 | EHMT2 (0.46) | EHMT2CYP2C9USP2LMNAABCC4 | |
| SCHEMBL23619186 | 0.85 | EHMT2 (0.46) | EHMT2CYP2C9USP2LMNAABCC4 | |
| SCHEMBL21265764 | 0.85 | EHMT2 (0.46) | EHMT2CYP2C9USP2LMNAABCC4 | |
| SCHEMBL30514375 | 0.85 | BRD4 (0.48) | EHMT2CYP2C9USP2LMNAABCC4 | |
| SCHEMBL21265744 | 0.85 | BRD4 (0.48) | EHMT2CYP2C9USP2LMNAABCC4 | |
| SCHEMBL30514369 | 0.85 | EHMT2 (0.45) | EHMT2CYP2C9USP2LMNAABCC4 | |
| SCHEMBL21265863 | 0.85 | EHMT2 (0.45) | EHMT2CYP2C9USP2LMNAABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. | 2021-07-08 | — | — | US | disclosed |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. | 2021-07-08 | — | — | US | disclosed |
| WO-2019157338-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | CYP3A43, CYP3A4, CYP4B1 | EHMT2 3071/4885CYP2C9 23/4885USP2 2299/4885 |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | CYP3A43, CYP3A4, CYP4B1 | EHMT2 3071/4885CYP2C9 23/4885USP2 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.